{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.2","upperLimit":"68.3","value":"62.9"},{"groupId":"OG001","lowerLimit":"68.8","upperLimit":"88.2","value":"79.7"},{"groupId":"OG002","lowerLimit":"69.9","upperLimit":"84.2","value":"77.6"},{"groupId":"OG003","lowerLimit":"74.6","upperLimit":"89.1","value":"82.8"},{"groupId":"OG004","lowerLimit":"50.1","upperLimit":"64.2","value":"57.2"},{"groupId":"OG005","lowerLimit":"11.0","upperLimit":"58.7","value":"31.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"116"},{"groupId":"OG004","value":"201"},{"groupId":"OG005","value":"16"}],"units":"Participants"}],"description":"Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days.\n\n* CR is defined as disappearance of all target lesions.\n* PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \\[SAD\\] for nodal lesions) of target lesions, taking as reference the baseline sum LD.\n\nORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG000","title":"Phase 2, Cohort 1: RET Fusion Solid Tumor"},{"description":"Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG001","title":"Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy"},{"description":"Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG002","title":"Phase 2, Cohort 3: RET Mutant MTC"},{"description":"Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG003","title":"Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy"},{"description":"Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \\[cfDNA+\\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG004","title":"Phase 2, Cohort 5: Advanced RET Altered Solid Tumor"},{"description":"Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG005","title":"Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants"}],"paramType":"NUMBER","populationDescription":"All phase 2 participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Approximately for up to 7 years 8 months","title":"Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}